GNLX

SEC source: 0001641172-25-026398 · ownership.xml · derivative · entry 6

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,568

Underlying: Common stock · 23,568 shares

Expires 2030-09-23

F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.

F1 · derivative.exercise_date: The shares subject to these options are fully vested.

SEC source: 0001641172-25-026398 · ownership.xml · derivative · entry 5

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 23,568 shares

Expires 2030-09-23

F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.

F1 · derivative.exercise_date: The shares subject to these options are fully vested.

SEC source: 0001641172-25-026398 · ownership.xml · derivative · entry 4

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,372

Underlying: Common stock · 157,372 shares

Expires 2030-03-22

F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.

F1 · derivative.exercise_date: The shares subject to these options are fully vested.

SEC source: 0001641172-25-026398 · ownership.xml · derivative · entry 3

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 157,372 shares

Expires 2030-03-22

F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.

F1 · derivative.exercise_date: The shares subject to these options are fully vested.

SEC source: 0001641172-25-026398 · ownership.xml · derivative · entry 2

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 925,000

Underlying: Common stock · 925,000 shares

Expires 2027-09-18

F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.

F1 · derivative.exercise_date: The shares subject to these options are fully vested.

SEC source: 0001641172-25-026398 · ownership.xml · derivative · entry 1

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 925,000 shares

Expires 2027-09-18

F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.

F1 · derivative.exercise_date: The shares subject to these options are fully vested.

SEC source: 0001641172-25-026396 · ownership.xml · derivative · entry 3

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,333

Underlying: Common stock · 8,333 shares

Expires 2030-09-23

F3 · price: The transactions reported herein reflect a one-time reduction of the exercise price of the stock option, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration date or the vesting schedule of the stock option.

F2 · derivative.exercise_date: The shares subject to the option vest as follows: 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001641172-25-026396 · ownership.xml · derivative · entry 2

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 8,333 shares

Expires 2030-09-23

F3 · price: The transactions reported herein reflect a one-time reduction of the exercise price of the stock option, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration date or the vesting schedule of the stock option.

F2 · derivative.exercise_date: The shares subject to the option vest as follows: 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001641172-25-026396 · ownership.xml · nonDerivative · entry 1

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,990

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common Stock upon vesting. The RSUs will vest 25% on the first anniversary of the grant date, and the remaining shares will vest in 12 equal quarterly (every 3 months) installments thereafter.

SEC source: 0001641172-25-026397 · ownership.xml · derivative · entry 4

Yu Yong · CIK 0001937482 · SVP, Clinical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common stock · 65,000 shares

Expires 2033-09-10

F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.

F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001641172-25-026397 · ownership.xml · derivative · entry 3

Yu Yong · CIK 0001937482 · SVP, Clinical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 65,000 shares

Expires 2033-09-10

F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.

F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001641172-25-026397 · ownership.xml · derivative · entry 2

Yu Yong · CIK 0001937482 · SVP, Clinical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,652

Underlying: Common stock · 207,652 shares

Expires 2029-09-20

F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.

F1 · derivative.exercise_date: The shares subject to the option are fully vested.

SEC source: 0001641172-25-026397 · ownership.xml · derivative · entry 1

Yu Yong · CIK 0001937482 · SVP, Clinical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 207,652 shares

Expires 2029-09-20

F2 · price: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.

F1 · derivative.exercise_date: The shares subject to the option are fully vested.

SEC source: 0001641172-25-025999 · ownership.xml · derivative · entry 2

Cappello Joseph · CIK 0001939198 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,500

Underlying: Common stock · 142,500 shares

Expires 2035-08-26

F2 · derivative.exercise_date: The shares subject to the option will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001641172-25-025999 · ownership.xml · nonDerivative · entry 1

Cappello Joseph · CIK 0001939198 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,766

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter.

SEC source: 0001641172-25-026003 · ownership.xml · derivative · entry 2

Thomas John · CIK 0001939103 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,576

Underlying: Common stock · 28,576 shares

Expires 2035-08-26

F2 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001641172-25-026003 · ownership.xml · nonDerivative · entry 1

Thomas John · CIK 0001939103 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 502,784

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001641172-25-026002 · ownership.xml · derivative · entry 2

Zindrick Thomas · CIK 0001937573 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 478,800

Underlying: Common stock · 478,800 shares

Expires 2035-08-26

F3 · derivative.exercise_date: The shares subject to the option will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001641172-25-026002 · ownership.xml · nonDerivative · entry 1

Zindrick Thomas · CIK 0001937573 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 554,161

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter.

F2 · balance_after: Includes 1514 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan.

SEC source: 0001641172-25-026000 · ownership.xml · derivative · entry 2

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,770

Underlying: Common stock · 34,770 shares

Expires 2035-08-26

F2 · derivative.exercise_date: The shares subject to the option will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001641172-25-026000 · ownership.xml · nonDerivative · entry 1

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,990

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter.

SEC source: 0001641172-25-026005 · ownership.xml · derivative · entry 2

Smither John W · CIK 0001559583 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,576

Underlying: Common stock · 28,576 shares

Expires 2035-08-26

F2 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001641172-25-026005 · ownership.xml · nonDerivative · entry 1

Smither John W · CIK 0001559583 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,994

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001641172-25-026001 · ownership.xml · derivative · entry 2

Yu Yong · CIK 0001937482 · SVP, Clinical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,520

Underlying: Common stock · 134,520 shares

Expires 2035-08-26

F3 · derivative.exercise_date: The shares subject to the option will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001641172-25-026001 · ownership.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · SVP, Clinical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,036

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter.

F2 · balance_after: Includes 916 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan.

SEC source: 0001641172-25-026006 · ownership.xml · derivative · entry 2

Tyree James L · CIK 0001324991 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,576

Underlying: Common stock · 28,576 shares

Expires 2035-08-26

F2 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001641172-25-026006 · ownership.xml · nonDerivative · entry 1

Tyree James L · CIK 0001324991 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,074

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001641172-25-026004 · ownership.xml · derivative · entry 2

Mirabelli Mary · CIK 0001937525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,576

Underlying: Common stock · 28,576 shares

Expires 2035-08-26

F2 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001641172-25-026004 · ownership.xml · nonDerivative · entry 1

Mirabelli Mary · CIK 0001937525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,284

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001493152-25-026981 · ownership.xml · nonDerivative · entry 1

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,746

F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2 · balance_after: The total shown in Column 5 takes into account the transactions reported on Forms 4 filed on August 29, 2025 and September 3, 2025.

SEC source: 0001493152-25-027337 · ownership.xml · nonDerivative · entry 2

Cappello Joseph · CIK 0001939198 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,033

F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2 · balance_after: The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025.

SEC source: 0001493152-25-027337 · ownership.xml · nonDerivative · entry 1

Cappello Joseph · CIK 0001939198 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,496

F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2 · balance_after: The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025.

SEC source: 0001493152-25-027338 · ownership.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · SVP, Clinical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,817

F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2 · balance_after: The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025.

SEC source: 0001493152-25-027339 · ownership.xml · nonDerivative · entry 1

Zindrick Thomas · CIK 0001937573 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 542,940

F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2 · balance_after: The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025, and 1,452 shares acquired under the Issuer's Employee Stock Purchase Plan on November 14, 2025.

SEC source: 0001415889-25-019032 · form4-07022025_080748.xml · derivative · entry 1

Groen Eric · CIK 0001918630 · General Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 270,000

Underlying: Common Stock · 270,000 shares

Expires 2035-06-30

F1 · derivative.exercise_date: 25% of the shares shall vest on July 1, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-25-018048 · form4-06242025_040601.xml · nonDerivative · entry 1

Thomas John · CIK 0001939103 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 480,501

SEC source: 0001415889-25-012806 · form4-05132025_050531.xml · nonDerivative · entry 1

Cappello Joseph · CIK 0001939198 · VP, Pharmaceutical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,266

F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

SEC source: 0001415889-25-012809 · form4-05132025_050537.xml · nonDerivative · entry 1

Ryder Sean · CIK 0001937485 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,621

F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

SEC source: 0001415889-25-012808 · form4-05132025_050535.xml · nonDerivative · entry 1

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,447

F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

SEC source: 0001415889-25-012807 · form4-05132025_050533.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,640

F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

SEC source: 0001415889-25-012805 · form4-05132025_050529.xml · nonDerivative · entry 1

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,760

F1 · kind: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

SEC source: 0001415889-25-010880 · form4-04172025_080429.xml · nonDerivative · entry 1

Cappello Joseph · CIK 0001939198 · VP, Pharmaceutical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,003

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of March 14, 2025.

SEC source: 0001415889-25-010881 · form4-04172025_080443.xml · nonDerivative · entry 1

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,019

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of March 14, 2025.

SEC source: 0001415889-25-010878 · form4-04172025_080416.xml · nonDerivative · entry 1

Ryder Sean · CIK 0001937485 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,096

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of March 14, 2025.

SEC source: 0001415889-25-010879 · form4-04172025_080423.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,219

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of March 14, 2025.

SEC source: 0001415889-25-010877 · form4-04172025_080409.xml · nonDerivative · entry 1

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,211

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of March 14, 2025.

SEC source: 0001415889-25-002798 · form4-02032025_110254.xml · derivative · entry 1

Pulisic Matthew · CIK 0002054836 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2035-01-30

F1 · derivative.exercise_date: 25% of the shares shall vest on January 30, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-24-030248 · form4-12312024_121226.xml · nonDerivative · entry 1

Tyree James L · CIK 0001324991 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,791

F1 · price: The weighted average sale price for the transaction reported was $2.46, and the range of prices were between $2.45 and $2.46. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-030004 · form4-12212024_011239.xml · derivative · entry 2

Cappello Joseph · CIK 0001939198 · VP, Pharmaceutical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,000

Underlying: Common Stock · 39,000 shares

Expires 2034-12-17

F2 · derivative.exercise_date: 25% of the shares vest on August 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-24-030004 · form4-12212024_011239.xml · nonDerivative · entry 1

Cappello Joseph · CIK 0001939198 · VP, Pharmaceutical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,653

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. 25% of the RSUs vest on August 1, 2025, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.